AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Theglobeandmail

Published November 4, 2026

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized ...

Read the full story at Theglobeandmail

Liechti, ME. “Modern clinical research on LSD .” Neuropsychopharmacology. 2017;42:2114-2127. View source version on businesswire.

Post on X

Share this story

Surfaced by 2 Google Alerts

LSD
Psychedelic press release